Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nephrosis, Lipoid Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced May 22, 2026, 1:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
2,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
trascutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Idiopathic Nephrotic Syndrome
Interventions
Standard of Care, UrApp
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 22, 2026, 1:26 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced May 22, 2026, 1:26 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Northridge, California • Victorville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced May 22, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Secretin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced May 22, 2026, 1:26 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
Interventions
FSGS/TR-MCD, Diabetic Nephropathy (DN)
Other
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Mesa, Arizona • Glendale, California • Victorville, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
VB119
Drug
Lead sponsor
Tenet Medicines
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced May 22, 2026, 1:26 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Interventions
Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
Transcutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions
frexalimab, brivekimig, rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Interventions
Serum and renal tissue analysis
Other
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Nephrosis, Focal Lipoid Glomerulosclerosis
Interventions
Oral dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
adalimumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced May 22, 2026, 1:26 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions
Biospecimen collection, Data collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 1:26 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions
Interview
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 22, 2026, 1:26 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Glomerular Disease
Interventions
Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced May 22, 2026, 1:26 AM EDT